Worldwide Bispecific Antibody Therapeutics Market (2019 to 2030) - Featuring AbbVie, Affibody, Affimed and Amgen Among Others - ResearchAndMarkets.com

DUBLIN--()--The "Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030" report has been added to ResearchAndMarkets.com's offering.

The Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030 report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics over the next decade. The study features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain.

The report also features the likely distribution of the current and forecasted opportunity across

  • Key therapeutic areas (genetic disorders, hematological malignancies, autoimmune disorders, infectious diseases, inflammatory disorders, eye disorders and skin disorders)
  • Different mechanisms of action (T-cell retargeting / activation, cytokines retargeting / neutralization, dual ligands blocking and others),
  • Key targets (CD3 x CD19, CD30 x CD16A, Factor IXa x Factor X, IL-13 x IL-4, IL-17A x Albumin, IL-17A x IL-17F, IL-1 x IL-1, Psl x PcrV, TNF- x HSA and VEGF-A x ANG-2)
  • Type of antibody formats (asymmetric, fragments, symmetric and others),
  • Key players (AbbVie, Affibody, Affimed, Amgen, AstraZeneca, Merck, Roche, Sanofi and Taisho Pharmaceutical) and
  • Key geographical regions (North America, Europe and Asia Pacific). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

Key Topics Covered:

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION

3.1. Chapter Overview

3.2. Concept of an Antibody

3.3. Structure of an Antibody

3.4. Functions of an Antibody

3.5. Mechanism of Action of an Antibody

3.6. Concept of Monoclonal Antibodies

3.7. Antibody Therapeutics

3.8. Historical Evolution of Antibody Therapeutics

3.9. Types of Advanced Antibody Therapeutics

3.10. Bispecific Antibody Formats

3.11. Mechanisms of Action of Bispecific Antibodies

3.12. Applications of Bispecific Antibodies

4. MARKET OVERVIEW

4.1. Chapter Overview

4.2. Bispecific Antibody Therapeutics: Developer Landscape

4.3. Bispecific Antibody Therapeutics: Clinical Pipeline

4.4. Bispecific Antibody Therapeutics: Early Stage Pipeline

4.6. Bispecific Antibody Therapeutics: Combination Therapy Candidates

4.7. Bispecific Antibody Therapeutics: Non-Industry Players

4.8. Emerging Novel Antibody Therapeutic Modalities

5. BISPECIFIC ANTIBODY THERAPEUTICS: TECHNOLOGY PLATFORMS

5.1. Chapter Overview

5.2. Bispecific Antibody Therapeutics: List of Technology Platforms

5.3. Bispecific Antibody Therapeutics: Technology Platform Profiles

5.4. Geographical Distribution of Technology Providers

5.5. Bispecific Antibody Technology Platforms: Comparative Analysis

6. DRUG PROFILES

6.1. Chapter Overview

6.2. Marketed Drug Profiles

6.3. Late Stage Drug Profiles

6.4. RG7716 / RO6867461 / Faricimab (Roche / Genentech)

6.5. Ozoralizumab / TS-152 / ATN103 (Ablynx / Eddingpharm / Taisho Pharmaceuticals)

6.6. ABT-165 (AbbVie)

6.7. ABY-035 (Affibody)

6.8. AFM13 (Affimed)

6.9. AMG 570 / MEDI0700 (Amgen)

6.10. KN026 (Alphamab)

6.11. KN046 (Alphamab)

6.12. M1095 / ALX-0761 (Merck / Ablynx / Avillion)

6.13. M7824 / Bintrafusp Alfa (Merck / GlaxoSmithKline)

6.14. MCLA-128 (Merus)

6.15. MEDI3902 / Gremubamab (MedImmune /AstraZeneca)

6.16. MEDI7352 (AstraZeneca)

6.17. REGN1979 (Regeneron)

6.18. ZW25 (Zymeworks)

7. KEY INSIGHTS

7.1. Chapter Overview

7.2. Bispecific Antibody Therapeutics: Analysis by Therapeutic Area and Phase of Development

7.3. Bispecific Antibody Therapeutics: Spider-Web Analysis based on Mechanism of Action

7.4. Bispecific Antibody Therapeutics: Two-Dimensional Scatter Plot Analysis based on Target Combinations

7.4.1 Key Parameters

7.5. Logo Landscape: Analysis of Developers by Company Size

8. BENCHMARK ANALYSIS: BIG PHARMA PLAYERS

8.1. Chapter Overview

8.2. Top Pharmaceutical Companies

8.2.1. Analysis by Target Antigen

8.2.2. Analysis by Type of Antibody Format

8.2.3. Analysis by Mechanism of Action

8.2.4. Analysis by Therapeutic Area

8.2.5. Analysis by Type of Partnership

9. PARTNERSHIPS AND COLLABORATIONS

9.1. Chapter Overview

9.2. Partnership Models

9.3. Bispecific Antibody Therapeutics: Partnerships and Collaborations

10. CONTRACT SERVICES FOR BISPECIFIC ANTIBODY THERAPEUTICS

10.1. Chapter Overview

10.2. Manufacturing of Bispecific Antibody Therapeutics

10.3. Key Considerations for Selecting a Suitable CMO / CRO Partner

11. CLINICAL TRIAL ANALYSIS

11.1. Chapter Overview

11.2. Methodology

11.3. Bispecific Antibody Therapeutics: Clinical Trial Analysis

12. CASE STUDY: REGULATORY GUIDELINES FOR BISPECIFIC ANTIBODIES

12.1. Chapter Overview

12.2. Guidelines Issued by Regulatory Authorities

12.2.1. US Food and Drug Administration (FDA)

12.2.2. World Health Organization (WHO)

12.2.3. The International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use

13. CASE STUDY: PROMOTIONAL / MARKETING STRATEGIES

13.1. Chapter Overview

13.2. Overview of Channels Used for Promotional Campaigns

13.3. Summary: Product Website Analysis

13.4. Summary: Patient Support Services and Informative Downloads

13.5. Promotional Analysis: Blincyto

13.6. Promotional Analysis: Hemlibra

14. SWOT ANALYSIS

15. MARKET FORECAST AND OPPORTUNITY ANALYSIS

15.1. Chapter Overview

15.2. Scope and Limitations

15.3. Forecast Methodology and Key Assumptions

15.4. Overall Bispecific Antibody Therapeutics Market, 2019-2030

15.5. Bispecific Antibody Market: Value Creation Analysis

15.6. Bispecific Antibody Therapeutics Market: Product-wise Sales Forecasts

16. CONCLUDING REMARKS

17. EXECUTIVE INSIGHTS

17.1. Chapter Overview

17.2. CytomX Therapeutics

17.3. F-star

17.4. Innovent Biologics

17.5. Synimmune

18. APPENDIX 1: TABULATED DATA

19. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

For more information about this report visit https://www.researchandmarkets.com/r/a109z3

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900